Focus Partners Advisor Solutions LLC Has $976,000 Position in Gilead Sciences, Inc. $GILD

Focus Partners Advisor Solutions LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 8,817 shares of the biopharmaceutical company’s stock after purchasing an additional 753 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Gilead Sciences were worth $976,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Smallwood Wealth Investment Management LLC acquired a new position in shares of Gilead Sciences in the 1st quarter valued at approximately $25,000. Activest Wealth Management grew its position in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the period. Harbor Asset Planning Inc. acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at approximately $27,000. Colonial Trust Advisors grew its position in shares of Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 213 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at approximately $34,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the sale, the chief executive officer owned 591,203 shares in the company, valued at approximately $66,013,726.98. This represents a 1.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the sale, the chief financial officer owned 157,055 shares in the company, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 61,500 shares of company stock worth $7,142,140. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Down 0.4%

NASDAQ GILD opened at $120.47 on Tuesday. Gilead Sciences, Inc. has a 12 month low of $86.08 and a 12 month high of $124.61. The stock has a 50 day moving average of $115.52 and a 200-day moving average of $111.21. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The company has a market cap of $149.48 billion, a PE ratio of 24.00, a PEG ratio of 0.83 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same quarter in the prior year, the business earned $2.01 EPS. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GILD has been the subject of several research reports. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target for the company in a research note on Tuesday, August 19th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Citigroup raised their price target on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Wednesday, October 8th. Cantor Fitzgerald raised their price target on shares of Gilead Sciences from $129.00 to $135.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Finally, The Goldman Sachs Group raised their price target on shares of Gilead Sciences from $105.00 to $108.00 and gave the stock a “neutral” rating in a research note on Friday, October 17th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $122.61.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.